Table 7.
Distribution of patients in subgroups by treatment with corresponding pCR rates
| n (pCR) | |||
| ddAT – Tamoxifen (n = 98) | ddAT + Tamoxifen (n = 98) | ||
| ER+ | HER2+ | 11 (1) | 10 (0) |
| HER2- | 46 (1) | 42 (0) | |
| HER2 status missing | 1 (0) | 0 (0) | |
| Total | 58 (2) | 52 (0) | |
| ER- | HER2+ | 12 (1) | 13 (0) |
| HER2- | 28 (6) | 33 (8) | |
| Total | 40 (7) | 46 (8) | |
| Total | 98 (9) | 98 (8) | |
ddAT, dose-dense Adriblastin (Doxorubicin) and Taxotere (Docetaxel); ER, oestrogen receptor; HER2, human epidermal growth factor receptor 2; pCR, pathological complete remission.